Garganta MD, et al. - In pediatric patients with osteogenesis imperfecta (OI) treated with intravenous bisphosphonate therapy, experts assessed pain and physical functioning. In children with OI, they noted a temporary reduction in pain and functional improvement with cyclic intravenous bisphosphonate therapy. Immediate relief in pain following infusion was noted and the functional improvements were observed 4 weeks later. By the time of the next infusion both pain and physical functioning revert to pretreatment levels.